BioCentury | Apr 13, 2018
Clinical News

Santhera's congenital muscular dystrophy candidate well tolerated in Phase I

...5-16 with congenital muscular dystrophy showing that once-daily 0.02-0.08 mg/kg doses of oral omigapil (SNT-317, TCH-346...
...study with regulatory authorities to determine next steps for advancing omigapil to a pivotal trial. Omigapil...
...Pharmaceuticals Holding AG (SIX:SANN), Liestal, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Omigapil (SNT-317, TCH-346...
BioCentury | Sep 5, 2016
Company News

Santhera musculoskeletal news

...Products Grants Program to support the ongoing open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating omigapil...
...congenital muscular dystrophy. Santhera expects to complete the trial next half. Santhera has rights to omigapil...
BioCentury | Aug 3, 2015
Clinical News

Omigapil: Completed Phase I enrollment

...the open-label, dose-escalation, U.S. Phase I CALLISTO trial evaluating 0.02, 0.08 and 0.2 mg/kg/day oral omigapil...
...AG (SIX:SANN), Liestal, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Omigapil ( SNT-317 , TCH-346...
BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: AMPA 2 glutamate receptor (GRIA2; GLUR2); glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

...of the peptide. Novartis AG and Santhera Pharmaceuticals Holding AG have omigapil ( SNT-317 ; TCH-346...
BioCentury | Jun 20, 2013
Distillery Therapeutics

Indication: Neurology

...Licensing status Publication and contact information Neurology Addiction; neurology Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Mouse studies suggest omigapil...
...addiction or overdose. In mice, omigapil decreased cocaine-mediated neurotoxicity compared with no treatment. In mice, omigapil...
...Abuse include evaluating the anticocaine effects of omigapil in animal models. Santhera Pharmaceuticals Holding AG's omigapil...
BioCentury | Jan 28, 2013
Emerging Company Profile

MD Pharma AB: Dialing down autophagy

...could be used in combination, and the company will explore this strategy in preclinical tests. Omigapil...
BioCentury | Apr 16, 2012
Company News

Santhera musculoskeletal news

...treatments with highly specific and well-defined modes of action. Santhera will develop a formulation of omigapil...
BioCentury | Jun 12, 2008
Targets & Mechanisms

Eyeing New Uses for Protease Inhibitors

A paper in the Journal of Clinical Investigation indicates that HIV protease inhibitors could be repurposed as neuroprotectants to block apoptosis in age-related macular degeneration, diabetic retinopathy and other conditions involving neuronal apoptosis. 1 The...
BioCentury | Mar 10, 2008
Clinical News

Omigapil: Phase II/III start

...Next half, Santhera plans to start a Phase II/III trial of omigapil (SNT-317) to treat CMD...
...Santhera Pharmaceuticals AG (SWX:SANN), Liestal, Switzerland Novartis AG (NYSE:NVS; SWX:NOVN), Basel, Switzerland Product: Omigapil ( SNT-317...
BioCentury | Jul 9, 2007
Company News

Santhera Pharmaceuticals AG, Novartis deal

...SANN received an exclusive license to develop NVS's omigapil ( SNT-317 ) to treat congenital muscular...
...remaining stock of the drug substance. SANN expects to start a Phase II trial of omigapil...
Items per page:
1 - 10 of 10